InflaRx N.V. (IFRX)
IFRX moved a median of 0.00% 30 minutes after news, and -0.72% by the close. How IFRX actually reacts to news — the realized, point-in-time move the market made, measured across 142 labeled events over the last three years with zero look-ahead.
IFRX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 34% | 140 |
| 30-min | 0.00% | 48% | 142 |
| 60-min | -0.81% | 42% | 142 |
| to close | -0.72% | 42% | 142 |
| Middle 50% of IFRX reactions | -2.81% to +1.40% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 142 |
Half of all InflaRx N.V. news events land between -2.81% and +1.40% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How IFRX reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 11 | -2.07% | 18% | +6.62% |
| Rating reiterations | 40 | +0.27% | 53% | -0.63% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 4 further classes were observed with fewer than 10 measured events and are not published. See how IFRX ranks against every other measured name →
That’s how IFRX usually reacts — get an email when it moves on news →Email me when IFRX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to IFRX's baseline. Nothing else.
Recent IFRX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| InflaRx to Present Late-Breaking Pre-clinical Data on Izicopan at Kidney Week 2026 | Press release | GlobeNewswire | +1.15% | -1.15% | |
| InflaRx Appoints Gabriela Alperovich, MD, PhD, as Senior Vice President & Global Head of Clinical Development | Press release | GlobeNewswire | -1.64% | -6.56% | |
| InflaRx to Host Virtual Capital Markets Day | Press release | GlobeNewswire | +3.20% | +0.47% | |
| InflaRx Announces Participation in September Investor Conferences | Press release | GlobeNewswire | -0.24% | -4.72% | |
| Form EFFECT InflaRx N.V. | SEC filing · Form EFFECT | SEC EDGAR | -0.25% | -0.49% | |
| Form 6-K InflaRx N.V. For: Aug 06 | SEC filing · Form 6-K | SEC EDGAR | -0.28% | -2.83% | |
| Form F-3 InflaRx N.V. | SEC filing · Form F-3 | SEC EDGAR | -0.28% | -2.83% | |
| Form S-8 InflaRx N.V. | SEC filing · Form S-8 | SEC EDGAR | -0.28% | -2.83% | |
| InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones | Press release | GlobeNewswire | -0.28% | -2.83% | |
| InflaRx to Report Second Quarter 2026 Results on August 6, 2026 | Press release | GlobeNewswire | +2.38% | +2.38% | |
| Form 6-K InflaRx N.V. For: Jun 30 | SEC filing · Form 6-K | SEC EDGAR | -2.23% | +4.02% | |
| InflaRx Assessing Feasibility of Broadened Strategy for ANCA-Associated Vasculitis in Europe Following EMA Recommendation on Tavneos | Press release | GlobeNewswire | -2.71% | +1.36% | |
| InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares | Press release | GlobeNewswire | -3.80% | +3.20% | |
| Form 6-K InflaRx N.V. For: May 07 | SEC filing · Form 6-K | SEC EDGAR | -3.80% | +3.20% | |
| Form 6-K InflaRx N.V. For: Mar 31 | SEC filing · Form 6-K | SEC EDGAR | +5.60% | +0.00% | |
| Form 6-K InflaRx N.V. For: May 06 | SEC filing · Form 6-K | SEC EDGAR | +5.60% | +0.00% | |
| InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal Diseases | Press release | GlobeNewswire | +5.60% | +0.00% | |
| InflaRx Announces Pricing of $150 Million Underwritten Offering of Ordinary Shares | Press release | GlobeNewswire | +5.60% | +0.00% | |
| Form 6-K InflaRx N.V. For: May 04 | SEC filing · Form 6-K | SEC EDGAR | +0.92% | -9.22% | |
| InflaRx Reports Favorable Reactive Metabolite Profile for Izicopan in Human Liver Microsomes | Press release | GlobeNewswire | -1.00% | +1.43% | |
| InflaRx to Report First Quarter 2026 Results on May 7, 2026 | Press release | GlobeNewswire | -0.73% | +2.94% | |
| Form 6-K InflaRx N.V. For: Apr 28 | SEC filing · Form 6-K | SEC EDGAR | +1.19% | +17.86% | |
| InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement | Press release | GlobeNewswire | +4.24% | +1.21% | |
| Form 6-K InflaRx N.V. For: Apr 23 | SEC filing · Form 6-K | SEC EDGAR | -1.86% | -8.07% | |
| Form 6-K InflaRx N.V. For: Apr 09 | SEC filing · Form 6-K | SEC EDGAR | -0.96% | -3.85% | |
| InflaRx Reports New Mechanistic Data for Izicopan Supporting its Potential as a Best-in-Class C5aR Inhibitor | Press release | GlobeNewswire | +0.02% | +6.47% | |
| Form 6-K InflaRx N.V. For: Apr 02 | SEC filing · Form 6-K | SEC EDGAR | +3.84% | +1.44% | |
| InflaRx Announces Participation in the Raymond James 2026 Biotech Innovation Symposium | Press release | GlobeNewswire | +2.06% | +6.48% | |
| InflaRx Highlights Clinical Activity of Vilobelimab in Pyoderma Gangrenosum in Late-Breaker Oral Presentation at 2026 American Academy of Dermatology Annual Meeting | Press release | GlobeNewswire | -6.12% | -10.57% | |
| Form 20-F InflaRx N.V. For: Dec 31 | SEC filing · Form 20-F | SEC EDGAR | +2.66% | +5.62% | |
| Form 6-K InflaRx N.V. For: Mar 19 | SEC filing · Form 6-K | SEC EDGAR | +2.50% | +4.55% | |
| InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones | Press release | GlobeNewswire | +2.50% | +4.55% | |
| InflaRx Announces Late-Breaker Oral Presentation on Vilobelimab Phase 3 Results in Pyoderma Gangrenosum at 2026 American Academy of Dermatology Annual Meeting | Press release | GlobeNewswire | -0.08% | -11.21% | |
| Form 6-K InflaRx N.V. For: Mar 13 | SEC filing · Form 6-K | SEC EDGAR | +0.16% | -5.04% | |
| InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement | Press release | GlobeNewswire | +0.16% | -5.04% | |
| InflaRx to Report Full Year 2025 Results on March 19, 2026 | Press release | GlobeNewswire | -1.47% | -3.83% | |
| InflaRx Announces Participation in the Leerink Partners Global Healthcare Conference | Press release | GlobeNewswire | -3.32% | -2.27% | |
| InflaRx Announces Participation in February Investor Conferences | Press release | GlobeNewswire | -0.48% | +0.69% | |
| Form 6-K InflaRx N.V. For: Jan 08 | SEC filing · Form 6-K | SEC EDGAR | -0.51% | -6.31% | |
| InflaRx Announces Strategy Focused on Capital-Efficient Execution with Izicopan and Near-Term Value Creation | Press release | GlobeNewswire | +0.83% | -9.92% | |
| Form 6-K InflaRx N.V. For: Dec 30 | SEC filing · Form 6-K | SEC EDGAR | +2.02% | +3.03% | |
| InflaRx Provides Update on Phase 3 Data Analyses for Vilobelimab in Pyoderma Gangrenosum | Press release | GlobeNewswire | +2.02% | +3.03% | |
| InflaRx Announces International Nonproprietary Name of “Izicopan” for INF904 | Press release | GlobeNewswire | -0.93% | -5.56% | |
| Form 6-K InflaRx N.V. For: Nov 10 | SEC filing · Form 6-K | SEC EDGAR | -2.95% | -10.73% | |
| Form 6-K InflaRx N.V. For: Sep 30 | SEC filing · Form 6-K | SEC EDGAR | -2.95% | -10.73% | |
| InflaRx Reports Positive Phase 2a Data for INF904 in Hidradenitis Suppurative (HS) and Chronic Spontaneous Urticaria (CSU) | Press release | GlobeNewswire | -2.95% | -10.73% | |
| InflaRx to Announce Topline Data from Phase 2a Clinical Trial of INF904 in Hidradenitis Suppurativa and Chronic Spontaneous Urticaria | Press release | GlobeNewswire | -2.95% | -10.73% | |
| InflaRx Announces Participation in the Guggenheim Securities 2nd Annual Healthcare Innovation Conference | Press release | GlobeNewswire | +0.00% | +1.49% | |
| Form 6-K InflaRx N.V. For: Sep 11 | SEC filing · Form 6-K | SEC EDGAR | -1.54% | -5.38% | |
| InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement | Press release | GlobeNewswire | -1.33% | -16.00% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the IFRX section they belong to.
Where else IFRX is measured.
IFRX earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Alimera Sciences, Inc. (ALIM) | 142 | 0.00% | 42% |
| G1 Therapeutics, Inc. (GTHX) | 142 | +0.21% | 66% |
| Oncocyte Corporation (OCX) | 141 | 0.00% | 47% |
| ImmunoGen, Inc. (IMGN) | 140 | +0.07% | 56% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is InflaRx N.V.'s median reaction calculated?
Every labeled IFRX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 142 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 48% of IFRX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does IFRX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.